Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia

The aim of this study is to identify and evaluate cardiotoxicity in patients with diagnosis of breast cancer, lymphoma or leukemia scheduled to receive anthracycline-based chemotherapy (Cohort A: prospective evaluation); and patients undergoing or having received within the last 5 years anthracycline-based chemotherapy (Cohort B: retrospective and prospective evaluations). Part A and B will be conducted in parallel. This study also has the objectif of identifying biomarkers of cardiotoxicity including inflammatory response proteins and clonal hematopoiesis.

Inclusion criteria

• Age 18 years or older at time of CT initiation
• Signed informed consent
• Patients with diagnosis of breast cancer,lymphoma or leukemia (including autografted subjects)
• Planned, ongoing or completed (within last 5 years) chemotherapy with anthracycline
• Left ventricular ejection fraction (LVEF) ≥50% pre-chemotherapy
• The participant is willing to undergo CMR scans and all other required study procedures

Exclusion criteria

• Known cardiomyopathy and/or LVEF <50%
• Known heart failure
• History of myocardial infarction (MI)
• Clinically significant cardiac valvular disease
• Clinically significant pericardial effusion
• Allografted subjects
• Contraindications to CMR testing (Cohort A & prospective evaluation for Cohort B):

• Pacemakers, other metallic implants or severe claustrophobia
• Weight > 135 kg
• Patients with a history of previous allergic reaction to gadolinium
• Patients with history of seizure
• Renal insufficiency (eGFR of < 45ml/min/1.73m2 using the MDRD equation)
• Pregnant or breastfeeding women